Anthracyclines disrupt telomere maintenance by telomerase through inducing PinX1 ubiquitination and degradation

• Published in: Oncogene Vol. 31; no. 1; pp. 1 - 12
• Main Authors: Zhang, B, Qian, D, Ma, H-H, Jin, R, Yang, P-X, Cai, M-Y, Liu, Y-H, Liao, Y-J, Deng, H-X, Mai, S-J, Zhang, H, Zeng, Y-X, Lin, M C, Kung, H-F, Xie, D, Huang, J-J
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 05.01.2012; Nature Publishing Group
• Subjects: Anthracycline; Anthracyclines; Anthracyclines - pharmacology; Apoptosis; Biodegradation; Cancer; Cell Biology; Cell Line, Tumor; Chemotherapy; Data processing; DNA Damage; Drug development; Health aspects; Human Genetics; Humans; Internal Medicine; Medicine; Medicine & Public Health; Oncology; original-article; Physiological aspects; Proteasome Endopeptidase Complex - physiology; Proteins; Telomerase; Telomerase - physiology; Telomere - drug effects; Telomeres; Tumor Suppressor Proteins - metabolism; Ubiquitin-proteasome system; Ubiquitination; China; cancer; telomerase; anthracyclines; telomere dysfunction; PinX1
• ISSN: 0950-9232; 1476-5594
• DOI: 10.1038/onc.2011.214

Telomere maintenance is essential for cancer growth. Induction of telomere dysfunction, for example, by inhibition of telomeric proteins or telomerase, has been shown to strongly enhance cancer cells’ sensitivity to chemotherapies. However, it is not clear whether modulations of telomere maintenance constitute cancer cellular responses to chemotherapies. Furthermore, the manner in which anti-cancer drugs affect telomere function remains unknown. In this study, we show that anthracyclines, a class of anti-cancer drugs widely used in clinical cancer treatments, have an active role in triggering telomere dysfunction specifically in telomerase-positive cancer cells. Anthracyclines interrupt telomere maintenance by telomerase through the downregulation of PinX1, a protein factor responsible for targeting telomerase onto telomeres, thereby inhibiting telomerase association with telomeres. We further demonstrate that anthracyclines downregulate PinX1 by inducing this protein degradation through the ubiquitin–proteasome-dependent pathway. Our data not only reveal a novel action for anthracyclines as telomerase functional inhibitors but also provide a clue for the development of novel anti-cancer drugs based on telomerase/telomere targeting, which is actively investigated by many current studies.